The global blood screening market size was valued at USD 2.76 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 11.7% from 2023 to 2030. Blood screening is a process in which donated blood is screened for infectious diseases such as HBV, HCV, HIV1, and HIV2. The high growth of this market is attributed to rising blood donations, an increase in the incidence of infectious diseases, and government initiatives. According to World Health Organization (WHO), 118.54 million blood donations are collected yearly. In the U.S., 6.8 million individuals donate blood annually, and 13.6 million units of red blood cells and whole blood are collected annually.
The market is primarily driven by the rise in the rate of disorders such as HIV, diphtheria, measles and chronic diseases such as hemophilia, cancer, and other blood-related disorders. Blood-based diagnostics are used to diagnose a wide range of diseases, including infectious diseases, cancer, and cardiovascular diseases. Serology tests detect the presence of antibodies to a specific disease-causing organism. These tests diagnose various infectious diseases, including HIV, hepatitis B, and syphilis. Molecular tests detect the presence of DNA or RNA from a specific disease-causing organism. These tests are more sensitive than serology tests and can be used to diagnose diseases at an earlier stage. Biochemical tests measure the levels of certain substances in the blood. These tests can diagnose a wide range of diseases, including diabetes, kidney disease, and liver disease.
The COVID-19 pandemic had a significant impact on the market. Although respiratory droplets are the primary means of COVID-19 virus transmission, research has shown that viral RNA may be discovered in blood samples, supporting blood screening for COVID-19 identification, hence driving the market significantly.
On the basis of product, the market is segmented into instruments and reagents. The reagent segment accounted for the largest revenue share of around 73.0% in 2022 and is expected to grow at the fastest CAGR of 12.0% over the forecast period owing to higher accuracy and specificity in detecting the presence and type of various elements in a small sample would drive the market.
The reagent market segment of the analysis includes chemical, biological, or immunological reagents, solutions, or products that the manufacturer intends to use in the blood screening process. In addition, reagents are cost-effective for customers and give the vendors a high return on investment. The high cost and reusable nature of instruments restrain the growth of the instrument segment in the market.
On the basis of technology, the market is segmented into nucleic acid amplification tests, ELISA, CLIA, EIA, NGS, and western blotting. The NAT segment accounted for the largest revenue share of 41.8% in 2022, owing to its high sensitivity and specificity for viral nucleic acid. The test detects nucleic acid earlier than other screening methods and, thus, narrows the window period of HBV, HCV, and HIV. According to the WHO, HIV has claimed 40.1 million lives till now and remains a global health concern with the current transmission in all countries where 1.5 million people attained HIV in 2021.
NAT was introduced in developed countries initially in the 1990s and early 2000s. About 33 countries in the world implemented NAT for HIV and around 27 countries for hepatitis B virus till 2014. The methods under this segment are polymerase chain reaction, ligase chain reaction, and transcription-mediated amplification.
ELISA accounted for the second-largest share of the market. The growth of this technology is attributed to continuous development to increase its specificity, low cost compared to NAT, and increasing prevalence of infectious diseases in the Asia Pacific region. There are various ELISA generations available in the market.
The Next Generation Sequencing (NGS) segment is expected to grow at the fastest CAGR of 16.3% during the forecast period owing to an increase in incidences of autism, connective tissue disorders, cancer, cardiomyopathies, and sex development disorders. According to a March 2023 WHO update, 1 in 100 children are diagnosed with autism.
North America dominated the market and accounted for the largest revenue share of 39.0% in 2022 owing to the presence of key industry players, increased adoption of the blood screening process, stringent FDA regulations for transfusion, rising infectious disease prevalence, and greater patient affordability are responsible for maintaining its position during the forecast period. The U.S. leads the market due to the local presence of leading players such as Roche Diagnostics, Abbott, and Danaher. One of the reasons for their continued dominance is the presence of well-established R&D infrastructure and favorable reimbursement policies.
According to the American Cancer Society, in 2022, around 1,918,030 new cases of cancer and about 609,360 cancer deaths are anticipated in the U.S. alone. In the U.S., 6.8 million individuals donate blood annually. These factors are expected to contribute to the continued dominance of the U.S. In addition, the regulatory and reimbursement landscape is continuously evolving to adapt to the fast-paced research progress in this sector. Moreover, the FDA is developing new regulatory strategies regarding NGS, which is anticipated to boost innovation in tests while ensuring that the data produced by these tests are accurate and reliable.
Asia Pacific is expected to grow at the fastest CAGR of 13.5% over the forecast period owing to increasing awareness about blood donation, rising patient affordability, and the focus of key industry players on emerging countries in the region. China, Japan, India, Singapore, and Australia are major contributing countries in the Asia Pacific region. In 2020, there were an estimated 12.7 million blood donations in India, while there were 15.5 million in China.
India’s market is a different scenario compared to the other Asia Pacific countries, such as China and Japan, owing to more relaxed regulatory guidelines and the import of most equipment & materials from other countries. Its market is expected to witness significant growth owing to increased investments by private and foreign entities, which can help provide effective tests at lower costs. The well-distributed network of clinical laboratories and hospitals in India is leading to faster adoption of blood screening techniques.
In India, testing for infectious diseases has increased demand for blood screening. Major infectious diseases, such as sexually transmitted diseases, HIV/AIDS, ventilator-acquired pneumonia, tuberculosis, and hospital-acquired infections, serve as key drivers for the market. Although blood screening is costlier and affordable only to the middle and mainly upper-tier economic group, rapid economic development is expected to increase the purchasing capacity of people. This factor, along with the demand for better diagnosis and preventive medicine, renders a promising outlook for India’s blood screening market.
Product launches, approvals, strategic acquisitions, and innovations are just a few of the important business strategies used by market participants to maintain and grow their global reach.
For instance, in March 2023, Abbott received U.S Food and Drug Administration (FDA) clearance for a laboratory traumatic brain injury blood test, the first commercially available lab-based test for the assessment of mild traumatic brain injuries (TBIs), commonly referred to as concussions, which will be made widely available to hospitals across the U.S. This test, which is powered by Abbott’s Alinity i laboratory tool, will enable clinicians to evaluate individuals with mild traumatic brain injuries in a timely manner.
Furthermore, in May 2023, Siemens Healthcare introduced Atellica HEMA 570 and 580 next-generation hematology analyzers, which have user-friendly interfaces and can be connected to multiple analyzers to remove workflow barriers and provide high throughput time.
Market size value in 2023
USD 3.06 billion
Revenue forecast in 2030
USD 6.62 billion
CAGR of 11.7% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Technology, product, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; Saudi Arabia; South Africa; UAE; Kuwait
Key companies profiled
Abbott; Danaher Corporation (Beckman Coulter); Becton Dickinson and Company; Bio-Rad Laboratories, Inc.; Hoffman-La Roche Ltd.; Grifols, S.A.; Ortho-Clinical Diagnostics, Inc.; Siemens Healthcare GmbH; Thermo Fisher Scientific, Inc.; SOFINA s.a (Biomerieux)
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global blood screening market based on technology, product, and region:
Technology Outlook (Revenue, USD Million, 2018 - 2030)
Nucleic Acid Amplification Test (NAT)
Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
Next Generation Sequencing
Product Outlook (Revenue, USD Million, 2018 - 2030)
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East and Africa
b. The global blood screening market size was estimated at USD 2.76 billion in 2022 and is expected to reach USD 3.06 billion in 2023.
b. The global blood screening market is expected to grow at a compound annual growth rate of 11.7% from 2023 to 2030 to reach USD 6.62 billion by 2030.
b. North America dominated the blood screening market with a share of 39.0% in 2022. This is attributable to the presence of key industry players, increased adoption of blood screening process, stringent FDA regulations for transfusion, and greater patient affordability.
b. Some key players operating in the blood screening market include Becton Dickinson and Company, Thermo Fisher Scientific., Ortho-Clinical Diagnostics, Inc., Grifols, Danaher Corporation (Beckman Coulter), Abbott Laboratories; Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd.; and Siemens Healthineers.
b. Key factors that are driving the market growth include rising blood donations, increase in the incidence of infectious diseases, and government initiatives.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."